Intentional disrupting PCSK9 activity by loss of function mutations (87), therapeutic PCSK9 protein antibodies, or siRNA mediated gene silencing (88), could significantly reduce circulating LDL-C levels, inhibit cardiomyocytes autophagy, and lower the risk of coronary heart disease. The gene discussed is PCSK9; the disease is coronary artery disorder.